First Commonwealth Financial Corporation (NYSE: FCF) ("First Commonwealth”) today announced that it has received all regulatory approvals required to complete the previously announced merger of ...
The results of COMP004 build upon previous findings from the Phase 2b trial COMP001, which showed that a single 25mg dose of COMP360 psilocybin was associated with a rapid and highly statistically ...
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has approved ...
ANVISA becomes the latest regulatory body worldwide to approve Illuccix ... if or when they have been approved; Telix's ...
Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...
Regulatory approval is issued independent of the IRB ... All documentation must be written in Japanese. To obtain IRB/IEC approval in Japan generally takes 4-8 weeks. Japan also operates a local ...
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback